0001178913-22-004137.txt : 20221123 0001178913-22-004137.hdr.sgml : 20221123 20221123160841 ACCESSION NUMBER: 0001178913-22-004137 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221121 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entera Bio Ltd. CENTRAL INDEX KEY: 0001638097 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38556 FILM NUMBER: 221416416 BUSINESS ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 BUSINESS PHONE: 972-2-532-7151 MAIL ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 8-K 1 form8k.htm 8-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 21, 2022
 
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
 
Israel
 
001-38556
 
00-0000000
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification)
 
KIRYAT HADASSAH, MINRAV BUILDING – FIFTH FLOOR, JERUSALEM, Israel 9112002
(Address of principal executive offices) (Zip Code)

+972-2-532-7151
(Registrant’s Telephone Number, Including Area Code)
  
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
 
ENTX
 
Nasdaq Capital Market
Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share
  
ENTXW
  
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
   
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing rule or Standard; Transfer of Listing.

On November 21, 2022, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s ordinary shares, par value of NIS 0.0000769 per share (the “ordinary shares”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the ordinary shares for the 30 consecutive business days prior to the date of the Notice.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 22, 2023, to regain compliance with the minimum bid price requirement. If at any time before May 22, 2023, the closing bid of the Company’s ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, then the Company will be deemed to have regained compliance with the minimum bid price requirement, following which, Nasdaq will provide a written confirmation of compliance and the matter will be closed.
 
If the Company is unable to regain compliance by May 22, 2023, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the minimum bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180 calendar day period, then Nasdaq will notify the Company of its determination to delist the ordinary shares, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.
 
The Company will monitor the closing bid price of its ordinary shares.  Receipt of the Notice has no effect on the Company’s business operations.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

   
ENTERA BIO LTD.
     
Date: November 23, 2022
By:
/s/ Miranda J. Toledano
   
Name: Miranda J. Toledano
Title: Chief Executive Officer
 
EX-101.SCH 2 entx-20221121.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 entx-20221121_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 entx-20221121_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Ordinary Shares, par value of NIS 0.0000769 [Member] Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member] EX-101.PRE 5 entx-20221121_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 21, 2022
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 21, 2022
Entity Registrant Name Entera Bio Ltd.
Entity Incorporation, State or Country Code L3
Entity File Number 001-38556
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One KIRYAT HADASSAH, MINRAV BUILDING
Entity Address, Address Line Two FIFTH FLOOR
Entity Address, City or Town JERUSALEM
Entity Address, Country IL
Entity Address, Postal Zip Code 9112002
City Area Code 972
Local Phone Number 97225327151
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001638097
Ordinary Shares, par value of NIS 0.0000769 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Ordinary Shares, par value of NIS 0.0000769
Trading Symbol ENTX
Security Exchange Name NASDAQ
Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share
Trading Symbol ENTXW
Security Exchange Name NASDAQ
XML 7 form8k_htm.xml IDEA: XBRL DOCUMENT 0001638097 2022-11-21 2022-11-21 0001638097 entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember 2022-11-21 2022-11-21 0001638097 entx:OrdinarySharesParValueOfNIS00000769Member 2022-11-21 2022-11-21 false 972 97225327151 0001638097 NASDAQ NASDAQ 8-K 2022-11-21 Entera Bio Ltd. L3 001-38556 00-0000000 KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM IL 9112002 false false false false Ordinary Shares, par value of NIS 0.0000769 ENTX Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share ENTXW true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !&!=U4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 1@7=5ZDMT K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OITE!)'1[6?&D(+B@> O)[&ZP^4,RTN[;V\;=+J(/X#$SOWSS M#4RGH]0AX7,*$1-9S#>3&WR6.F[8D2A*@*R/Z%2NYX2?F_N0G*+YF0X0E?Y0 M!P31-+?@D)11I& !5G$ELKXS6NJ$BD(ZXXU>\?$S#05F-." #CUEX#4'UB\3 MXVD:.K@"%AAA0<.;T^/+V7=ROI, MRFNZ!]:(1HN*\$NU.<-G&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M$8%W55PZ"P,U!0 -!< !@ !X;"]W;W)K)@Y5>Q2A(\\T*MNI54A 5O0=:@G8G/#]@]4-WJ^"%7ZGVSV MUUH5XJ^5%M&^,1!$/-Y]TNV^$,+Q7Y,H0+B*=9 MI/XNHMNIG16KF3%^KA+JLVX%!K%B\HE5>C_]8#>L7Q%6-V-U,?6\F+/GA!7! MX#M%S14#.&H9QSUXXHQ9I(+,[@" D.T ML"ZX4C:DRL94(T-KH(+[,35A2QA5D@+CB$:%8*4Z3%)RP049ZJ"*D#4SLN8Q M9%[L"YD(F<[!$S+54#,C):1W,F MBT!P#-H93_L8GAG=$B^ X<87W$_+AM#ABI9U:NW^$#S;R@W6 M.@:P'P1@..KDY8"D/G8?%_9CB>2M-_FS/R,W_:O^=-J_.2%WWFC2_TPN'KSA ME3?ZA'&_"@;[X]RSC2CDQB4'WF!V0P;#^_L)AIA'@XVZ^3O$2W,&TV0F-L7) MA0"U?RAAA0G@LV;NS_!1H+I6E(_N+) M03\I46S;-JS^,$>V\[2P<9-/^ZX/"\O#,+A NXF"Y-E@XZ8^%#Y49;P2,69P M)2( X]1=IVG7;0PJCP4;M^Y'R;5F,=0FBM;QWN%4(1@N5);N=IX#-F[B4Q%R MGYM%&;F#>)*=.26W++B M6N%2L,ZP&V[+:C)XN#!P+,J\#,^>ES-!>%#EXB<#V:_8&1Y('B ME 3*OF@PV_T5C9?LX%M9B="H/[WJ_XXQY:'BX"'P2*5Y/X1N8-1?D?TI85LF M?:[H'#I] 0O.%0T7IGMH3-[V'Z%F9^7E>D82R?VT(W^L5UMUDAC[?]L G9,H M[$+IUWYS"X1,#/[ M$4-YM2^&9]SQ4[M$Z/#4KKW: S7[R7?4K&44"=D"E*QJ$P)"[K9H=R=:).FV MZ%QH+:+T<,4H+,C,!?#[0@C]&PO9KEMWDOSA MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!> M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V& M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V; MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \ M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^ M8* \^>Q\ETWLJ.?]74_P$4$L#!!0 M ( !&!=U67BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 3 24 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://enterabio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:CityAreaCode, dei:LocalPhoneNumber, dei:SecurityExchangeName - form8k.htm 11 form8k.htm entx-20221121.xsd entx-20221121_def.xml entx-20221121_lab.xml entx-20221121_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "entx-20221121_def.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "entx-20221121_lab.xml" ] }, "presentationLink": { "local": [ "entx-20221121_pre.xml" ] }, "schema": { "local": [ "entx-20221121.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 36, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 0, "nsprefix": "entx", "nsuri": "http://enterabio.com/20221121", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20221121to20221121", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://enterabio.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20221121to20221121", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "entx_OrdinarySharesParValueOfNIS00000769Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares, par value of NIS 0.0000769 [Member]" } } }, "localname": "OrdinarySharesParValueOfNIS00000769Member", "nsuri": "http://enterabio.com/20221121", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]" } } }, "localname": "WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember", "nsuri": "http://enterabio.com/20221121", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://enterabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001178913-22-004137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-22-004137-xbrl.zip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end